Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Posted by Brian Himes on Jun 21st, 2026

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX – Get Free Report) has earned a consensus rating of “Moderate Buy” from the six analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $11.00.

A number of brokerages recently weighed in on EVAX. JonesTrading began coverage on Evaxion A/S in a report on Tuesday, March 10th. They issued a “buy” rating and a $10.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Evaxion A/S in a report on Friday, April 24th. Wall Street Zen cut Evaxion A/S from a “buy” rating to a “hold” rating in a research note on Sunday, March 22nd. Lake Street Capital reduced their price objective on Evaxion A/S from $11.00 to $9.00 and set a “buy” rating on the stock in a research note on Monday, March 9th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Evaxion A/S in a research note on Thursday, June 11th.

Get Our Latest Research Report on EVAX

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Evaxion A/S during the fourth quarter worth about $38,000. Wesbanco Bank Inc. acquired a new position in shares of Evaxion A/S during the fourth quarter worth about $48,000. SmartHarvest Portfolios LLC acquired a new position in shares of Evaxion A/S during the fourth quarter worth about $72,000. Annis Gardner Whiting Capital Advisors LLC acquired a new position in shares of Evaxion A/S during the first quarter worth about $112,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Evaxion A/S during the first quarter worth about $146,000. Institutional investors and hedge funds own 11.04% of the company’s stock.

Evaxion A/S Price Performance

Shares of Evaxion A/S stock opened at $3.05 on Friday. Evaxion A/S has a twelve month low of $2.19 and a twelve month high of $12.15. The stock has a market capitalization of $25.44 million, a P/E ratio of -2.07 and a beta of 0.24. The company has a current ratio of 5.85, a quick ratio of 5.85 and a debt-to-equity ratio of 0.41. The business’s fifty day moving average price is $3.99 and its 200 day moving average price is $4.15.

Evaxion A/S (NASDAQ:EVAX – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.43). As a group, research analysts anticipate that Evaxion A/S will post -0.5 earnings per share for the current year.

Evaxion A/S Company Profile

(Get Free Report)

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.